Trade this ETF at your broker
Fund size | EUR 364 m |
Total expense ratio | 0.35% p.a. |
Replication | Physical (Optimized sampling) |
Legal structure | ETF |
Strategy risk | Long-only |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 17.67% |
Inception/ Listing Date | 19 October 2017 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | iShares |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | State Street Fund Services (Ireland) Limited |
Investment Advisor | |
Custodian Bank | State Street Custodial Services (Ireland) Limited |
Revision Company | Deloitte |
Fiscal Year End | 31 May |
Swiss representative | BlackRock Asset Management Schweiz AG |
Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | ESTV Reporting | |
Austria | Tax Reporting Fund | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
Securities lending | Yes |
Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
VERTEX PHARMACEUTICALS ORD | 9.61% |
GILEAD SCIENCES INC | 9.49% |
AMGEN INC | 9.22% |
REGENERON PHARMACEUTICALS INC | 8.72% |
SEAGEN INC ORD | 4.49% |
ASTRAZENECA PLC ADR | 4.14% |
BIOGEN INC | 3.87% |
MODERNA INC | 3.25% |
ALNYLAM PHARMACEUTICALS ORD | 2.13% |
ILLUMINA INC | 1.95% |
United States | 84.71% |
Ireland | 1.57% |
Germany | 1.15% |
Other | 12.57% |
Health Care | 89.57% |
Other | 10.43% |
Broker | Rating | Savings plan offer | Brokerage fee | More information |
---|---|---|---|---|
![]() | free of charge | free of charge | More info | |
![]() | free of charge | free of charge | More info | |
![]() | free of charge | free of charge | More info | |
![]() | free of charge | free of charge | More info | |
![]() | free of charge | free of charge | More info |
YTD | -7.22% |
1 month | +0.76% |
3 months | -4.87% |
6 months | -5.39% |
1 year | -12.60% |
3 years | -3.48% |
5 years | +26.08% |
Since inception (MAX) | +24.88% |
2022 | -5.02% |
2021 | +7.94% |
2020 | +15.18% |
2019 | +27.25% |
Volatility 1 year | 17.67% |
Volatility 3 years | 23.68% |
Volatility 5 years | 25.93% |
Return per risk 1 year | -0.71 |
Return per risk 3 years | -0.03 |
Return per risk 5 years | 0.26 |
Maximum drawdown 1 year | -17.41% |
Maximum drawdown 3 years | -30.93% |
Maximum drawdown 5 years | -30.93% |
Maximum drawdown since inception | -30.93% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | 2B70 | - - | - - | - |
Stuttgart Stock Exchange | EUR | 2B70 | - - | - - | - |
Bolsa Mexicana de Valores | MXN | - | BTEC1N MM | BTEC1N.MX | |
London Stock Exchange | USD | BTEC | BTEC LN INAVBTEU | BTEC.L 0WXSINAV.DE | |
London Stock Exchange | GBP | BTEK | BTEK LN INAVBTEU | BTEK.L 0WXSINAV.DE | |
SIX Swiss Exchange | USD | BTEC | BTEC SE INAVBTEU | BTEC.S 0WXSINAV.DE | |
XETRA | EUR | 2B70 | 2B70 GY INAVBTEE | BTEC.DE 0WXNINAV.DE |
Fund name | Fund Size in m € (AuM) | TER in % p.a. | Distribution policy | Replication method |
---|---|---|---|---|
Invesco Nasdaq Biotech UCITS ETF | 461 | 0.40% p.a. | Accumulating | Swap-based |
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 35 | 0.35% p.a. | Distributing | Sampling |